The primary endpoints of the human trial for GLPG0974 will be to determine the pharmacokinetics and to evaluate biomarker effects of this candidate drug.
The placebo-controlled, double-blind, single ascending dose study will evaluate the safety and tolerability of a wide dose range.
Galapagos CEO Onno van de Stolpe said GSK has decided to return the GPR43 program to Galapagos, and consequently we will not receive a milestone for initiation of this study.
"We are encouraged by the results of this program thus far and have made the decision to continue moving forward with GLPG0974 on our own," van de Stolpe added.